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Lumbar spine.Oral risedronate has been shown to be effective in the treatment of osteoporosis when administered once-daily or
once-weekly in Japan. This randomized, double-blind, multicenter 12-month study was conducted to compare the
efﬁcacy and tolerability of oral risedronate 75 mg once-monthly with 2.5 mg once-daily in Japanese patients with
involutional osteoporosis. Bone mineral density (BMD), biochemical markers of bone metabolism, fractures, and
adverse events (AEs) were evaluated. At the end of the study (Month 12, last observation carried forward [M12,
LOCF]), mean percent change (SD) from baseline in lumbar spine (L2–L4) BMD,measured by dual energy X-ray ab-
sorptiometry (primary endpoint), was increased by 5.69 (4.00)% in the 2.5 mg once-daily group (n = 428), and
5.98 (4.54)% in the 75 mg once-monthly group (n = 422). In the non-inferiority t-test (non-inferiority margin
Δ = 1.5%), the 75 mg once-monthly groupwas non-inferior to the 2.5 mg once-daily group (p b 0.0001). The dif-
ference between treatment groups was 0.28% (95% CI,−0.31% to 0.88%). Changes in biochemical markers of bone
metabolismwere generally comparable in the two groups, although decreases in the percent change from baseline
in urinary NTX/CRN and CTX/CRN were statistically greater in the 2.5 mg once-daily group than the 75 mg once-
monthly group. The frequency of new vertebral fractures (including aggravation of prevalent fractures) at the
end of the study (M12, LOCF) was also similar in the two groups: 1.2% in the 2.5 mg once-daily group and 1.3%
in the 75 mg once-monthly group.
The incidence ofmild/moderate/severeAEswas 75.5%/6.3%/0.5% in the 2.5 mgonce-daily group and77.7%/8.1%/0.7%
in the 75 mg once-monthly group. AEs associated with gastrointestinal symptoms occurred in approximately 30%
of subjects in each group but with no severe cases. AEs potentially associated with acute phase reaction (including
symptoms of inﬂuenza-like illness or pyrexia starting within 3 days of the ﬁrst dose of the study drug and with a
duration of 7 days or less) only occurred in the 75 mg once-monthly group (2.1%, 9/422 subjects; inﬂuenza-like
symptoms in 1 subject and pyrexia in 8 subjects), although the incidence was low without any severe cases.
In conclusion, risedronate 75 mg once-monthly (a dosage which is 30 times higher than risedronate 2.5 mg
once-daily) had non-inferior efﬁcacy in terms of BMD and was similarly well tolerated compared to the once-
daily regimen in Japanese patients with involutional osteoporosis. Consistent with the once-daily and once-
weekly dosage, the once-monthly dosage of risedronate 75 mg was half that used outside Japan (150 mg).
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND licenseIntroduction
Globally, the antiresorptive bisphosphonates have been used
extensively for the treatment of osteoporosis. In Japan, for example,Rehabilitation Division, Tottori
).
c. Open access under CC BY-NC-ND lialendronate and risedronate are frequently used as strongly recom-
mended pharmacotherapy in the treatment of osteoporosis [1], and
minodronate has also been approved for this indication [1]. Risedronate
2.5 mg once-daily was shown to be effective in preventing vertebral
fractures in patients with involutional osteoporosis in Japan [2]. Numer-
ous clinical studies have shown that most oral bisphosphonates that
were originally developed for once-daily administration demonstrate
equivalent, or non-inferior, efﬁcacy and tolerability with once-weekly
and/or monthly dosing regimens [3–7]. In these studies, the dosages
used in Japan (alendronate 5 mg daily/35 mg weekly; risedronate
2.5 mg daily/17.5 mg weekly) were half the dosage used outsidecense.
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35 mg weekly) [2–6]. The difference in oral bisphosphonate dosages
between Japanese and subjects outside Japan suggested a difference
in bioavailability between Japanese and non-Japanese individuals,
although the reasons for this difference remain unknown [8].
Adherence to the treatment regimen is important for osteoporosis
but there are a number of obstacles to adherence. Since osteoporosis
is a chronic disease requiring long-term clinical management, some
patients may have problems complying with medication instructions
consistently and ﬁnd them burdensome. Indeed, it has been reported
that patients who are poorly adherent to bisphosphonate therapy do
not maintain the same level of improvement in bone mineral density
(BMD) [9–11]. Moreover, non-adherence with antiresorptive therapy
has been reported frequently and it has been reported to result in a
16–50% increased risk of fracture [9–12].
In Japan, a once-weekly regimen improved treatment adherence
to bisphosphonates, which was a problem associated with once-daily
products. Nevertheless, 20% or more patients stopped taking the drug
after 6 months of treatment [13].
From the results of online surveys of Japanese patients and patients
outside Japan taking bisphosphonates, it was shown that patients tended
to prefer once-monthly products to once-daily or once-weekly products
because of the lower frequency of administration [13–17]. Furthermore,
treatment adherence with once-monthly and once-weekly dosage
regimens has also been evaluated in clinical studies outside Japan, and
once-monthly products provided improved treatment adherence com-
pared with once-weekly products [14]. Monthly administration is ex-
pected to improve treatment adherence in Japanese patients receiving
long-termbisphosphonate therapywho are having difﬁculty complying
with daily or weekly dosage regimens [15,18,19].
The aim of this randomized, double-blind study was to compare,
in patients with involutional osteoporosis, the efﬁcacy and tolerability
of oral risedronate 2.5 mg once-daily with that of 75 mg once-monthly,
which is 30 times larger than the recommended daily dose and half the
monthly dose (150 mg) used outside Japan [7]. This is consistent with
the daily and weekly doses (2.5 mg and 17.5 mg, respectively) used in
Japan, being half the daily and weekly doses (5 mg and 35 mg, respec-
tively) used outside Japan. Risedronate 75 mg once-monthly has been
approved in Japan since 25 December 2012.
Methods
Study design
This was a 12-month, phase III, multicenter, randomized, double-
blind, parallel group, active comparator controlled study in Japanese
patients with involutional osteoporosis.
Diagnosis of osteoporosis was based on the presence or absence of
fragility fracture and BMD measurements speciﬁed in the “Guideline
for the Diagnosis of Primary Osteoporosis (2000 Revised Version)”
established by the Japanese Society for Bone and Mineral Research
[20,21].
Patients
Individuals eligible for this study were ambulatory Japanese male
and female subjects aged≥50 yearswhowere diagnosedwith osteopo-
rosis, based on the criteria for primary osteoporosis of the Japanese
Society for Bone and Mineral Research [20,21]. Primary osteoporosis
was deﬁned by the presence of a fragility fracture and BMD b80% of
the ‘young adult mean’ (20 to 44 years of age), or BMD b70% of the
‘young adult mean’ in the absence of a detectable fragility fracture
[21]. In the case of female subjects, ≥2 years must have passed since
menopause.
The main exclusion criteria were factors which affect efﬁcacy evalu-
ation; secondary osteoporosis and any other disease causing decreasedbone mass or affecting lumbar spine BMD (including severe scoliosis of
the spine, fracture or severe deformation in any of the L2–L4 lumbar
vertebrae, or a spinal X-ray image suggesting severe bone sclerosis
[calciﬁcation] in any of the L2–L4 lumbar vertebrae); administration of
bisphosphonate within 24 weeks before the ﬁrst dose of the study
drug; administration of any drug affecting bone metabolism such as
SERMs, vitamin D3 and vitamin K2 preparations, and calcitonin analogs,
etc. within 8 weeks before the ﬁrst dose of the study drug. In addition,
any subject judged by the attending physician to be unsuitable to partic-
ipate in the study was also excluded.
Procedures
The studywas performed at 60 study sites in Japan between February
2010 and August 2011 in accordancewith the ethical principles set out in
the Declaration of Helsinki and the ICH Harmonized Tripartite Guideline
for Good Clinical Practice, and was approved by the Institutional Review
Boards at each study site in line with local regulations. Prior to study
registration, all subjects were given a full explanation of the study pro-
cedures and provided written informed consent.
Subjects fulﬁlling the inclusion/exclusion criteria were eligible for the
study and were randomized (in a ratio of 1:1) to receive risedronate
75 mg once-monthly or risedronate 2.5 mg once-daily. Matching
2.5 mg and 75 mg placebo tablets were administered tomaintain double
blindness throughout the study. Subjects were instructed to take a single
75 mg risedronate tablet or 75 mg placebo tablet on the same calendar
day eachmonth and a single 2.5 mg risedronate tablet or 2.5 mg placebo
tablet at the designated time on every day. The subjects were instructed
to take the medication with water immediately upon waking in the
morning and not to lie down for at least 30 min after swallowing the tab-
let. During this 30-min period, the subjectswere required to avoid eating,
drinking (other than water for taking risedronate) or taking any other
medications. Supplementary calcium lactate (containing 200 mg Ca2+)
was administered orally once daily after dinner from the registration
date until the end of the study. Concomitant use of any drug considered
to affect bone metabolism, including vitamin D, was prohibited during
the study.
The study comprised a screening phase followed by a 12-month
double-blind treatment phase, and each subject was required to visit
the study site on Day 15 after the ﬁrst dose of the study drug (with
Day 1 being the ﬁrst treatment day) and then monthly for a total of
12 months.
Measurements
Efﬁcacy
Lumbar spine (L2–L4) BMDwasmeasured at baseline, and after 6 and
12 months (or upon discontinuation) by dual energy X-ray absorptiome-
try (DXA) using a QDR system (model: Hologic QDR-4500 or higher). At
each study site, investigators carried out “accuracy control calibration”
using a lumbar standard phantom attached to the equipment before the
ﬁrst measurement on the subjects at each measurement date, and
checked that BMD was within acceptable limits (±1.5% of phantom
values). X-ray images of thoracic vertebra and lumbar spine were taken
at baseline and after 12 months (or upon discontinuation).
Two central independent committees were established for DXA
assessment and for X-ray assessment. The central committee for DXA
assessment conﬁrmed whether subjects fulﬁlled inclusion/exclusion
criteria and whether BMD measurement results were eligible. The
central committee for X-ray assessment conﬁrmed fragility fracture
and evaluated vertebral fracture.
The assessment of prevalent fracture was made if the ratio of the
central vertebral height to the anterior (C/A) or posterior vertebral
body height (C/P) was less than 0.8, or the ratio of the anterior to poste-
rior vertebral body height (A/P) was less than 0.75, or if the anterior,
central, and posterior vertebral heights were decreased by more than
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new or worsening vertebral fracture was judged if any one of the three
vertebral heights (A, C, or P), had decreased by at least 20% and by 4 mm
in a vertebra diagnosed grade progression by semiquantitative assess-
ment [22].
Compliance with treatment was determined by returned tablet
counts and interviews with subjects at each clinic visit. DXA and X-ray
were not required in subjects who discontinued treatment within
84 days after the ﬁrst dose of the study drug.
Biochemical markers of bone metabolism were measured at
baseline, and after 1, 3, 6, 9, and 12 months (or upon study discontinu-
ation). Biochemical markers of bone metabolism included serum BAP
(bone alkaline phosphatase), serum TRACP-5b (tartrate-resistant acid
phosphatase 5b), urinary DPD/CRN (deoxypyridinoline, adjusted for
creatinine), urinary NTX/CRN (cross-linked N-telopeptides of type 1
collagen, adjusted for creatinine), and urinary CTX/CRN (cross-linked
C-telopeptide of collagen type 1, adjusted for creatinine). Serum BAP
wasmeasured by chemiluminescent enzyme immunoassay on an auto-
matic analyzer (UniCel DxI 800, Beckman Coulter, LaBrea, CA) using
Access Ostase reagent. Urinary NTX was measured by enzyme-linked
immunosorbent assay on an automated machine (NIPPON ADVANCED
TECHNOLOGY, Ibaraki, Japan) using Osteomark (Alere Health, Tilburg,
The Netherlands); the intra- and inter-assay coefﬁcients of variation
were below 7% and 6%, respectively. Urinary CTX was measured using
an enzyme immunoassay kit (Urine BETACrossLaps®ELISA, Nordic Bio-
science Diagnostics, Herlev, Denmark). The results of the biochemical
markers of bonemetabolism assaysweremeasured at SRL, a central lab-
oratory in Hachioji-shi, Tokyo, Japan, using standard methods.Safety
Safety was evaluated by the records of all adverse events (AEs), vital
signs, and clinical laboratory test values (hematology, biochemistry and
urinalysis). Investigators asked the subjects questions about subjective
symptoms at each visit and took vital signs, and clinical laboratory
test values at baseline, and after 0.5, 3, 6, 9, and 12 months. AEs were
coded usingMedical Dictionary for Regulatory Activities (MedDRA) ver-
sion 14.1. The incidence of AEs was calculated in each treatment group.
AEs counted as non-vertebral fractures included all fractures except
those occurring in vertebra. Gastrointestinal symptoms included events
that were classiﬁed in accordance with the MedDRA system organ class
(SOC) as “gastrointestinal disorders”, excluding the preferred terms refer-
ring to oral and anal conditions, but including the preferred terms “gas-
troenteritis”. Adverse events potentially associated with acute phase
reaction (APR) included symptoms of inﬂuenza-like illness or pyrexia
with a starting date within the ﬁrst 3 days after the ﬁrst dose of study
drug and a duration of 7 days or less.Fig. 1. DispositionStatistical analysis
Three types of analysis setswere used. The full analysis set (FAS)was
deﬁned as all subjects who were randomized and received at least one
dose of the study drug. The per-protocol set (PPS) was deﬁned as all
FAS subjects who had no major protocol deviation, fulﬁlled minimum
protocol requirements, and whose primary endpoint was evaluable.
The safety analysis set was deﬁned as all subjects who received at
least one dose of the study drug.
The primary endpoint was mean percent change from baseline in
lumbar vertebrae (L2–L4) BMD measured using DXA at the end of the
study (Month 12with the last observation carried forward, hereafter re-
ferred to asM12, LOCF). A non-inferiority t-test (non-inferioritymargin
Δ = 1.5%, one-sided type I error = 2.5%) was performed as the primary
analysis, to compare the primary endpoint between the 75 mg once-
monthly group and the 2.5 mg once-daily group in FAS.
Secondary analysis consisted of the same analysis as the primary
using PPS to ensure the robustness of the results. Summary statistics
using FAS were also calculated for mean percent change from baseline
in (L2–L4) BMD at 6 and 12 months.
Secondary endpoints were analyzed using FAS. Mean percent
change from baseline was calculated for biochemical markers of bone
metabolism at 1, 3, 6, 9, 12 months, and at the end of the study (M12,
LOCF). Vertebral fractures were also examined at 12 months and at
the end of the study (M12, LOCF) by calculating the frequency, as well
as the difference between the treatment groups and the 95% conﬁdence
intervals (CI).
Subgroup analysis on the primary endpoint was performed using
the baseline values of the biochemical markers.Results
Baseline patient characteristics
A total of 1251 individuals provided written informed consent and,
of these, 852 subjects (429 subjects in the 2.5 mg once-daily group
and 423 subjects in the 75 mg once-monthly group) were enrolled
into the study and randomized (Fig. 1). A subject who had registered
twice was excluded from all analyses, and the FAS comprised 850 sub-
jects (428 subjects in the 2.5 mg once-daily group and 422 subjects in
the 75 mg once-monthly group). The PPS group included 711 subjects
(368 subjects in the 2.5 mg once-daily group, and 343 subjects in the
75 mg once-monthly group). Study discontinuation or withdrawal
occurred in 48 and 58 subjects, respectively, in the 2.5 mg once-daily
and 75 mg once-monthly groups. Pretreatment events, which were de-
ﬁned as any untoward medical occurrence in a subject who had signedof subjects.
Fig. 2. Mean percent change from baseline in lumbar spine (L2–L4) BMD (FAS). End of
study refers to the value calculation using the last observation carried forward at Month
12. Therewere no statistically signiﬁcant differences between groups at anymeasurement
time points. Non-inferiority validation at the end of treatment (Δ = 1.5%): t = 5.90
(p b 0.0001); intergroup difference 0.28, two-sided 95% CI−0.31 to 0.88.
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istration of any study medication, and adverse events were the most
common reasons for discontinuation or withdrawal in both groups
through the treatment period.
A summary of baseline demographics and characteristics of random-
ized subjects is presented in Table 1. With the exception of CTX/CRN
levels, which were slightly higher in the 2.5 mg once-daily group com-
pared with the 75 mg once-monthly group, all key baseline demo-
graphics and primary disease characteristics were similar in the two
treatment groups. Patient characteristics at baseline in the PPS were
similar to those of the randomized set.
Efﬁcacy
Bone mineral density
Mean percent change (SD) from baseline in (L2–L4) BMD at the end
of the study (M12, LOCF) in the FAS was 5.69 (4.00)% in the 2.5 mg
once-daily group and 5.98 (4.54)% in the 75 mg once-monthly group.
In the non-inferiority t-test, the 75 mg once-monthly group proved
to be non-inferior to the 2.5 mg once-daily group (p b 0.0001). The
difference between treatment groups was 0.28% (95% CI, −0.31% to
0.88%). Mean percent change from baseline in (L2–L4) BMD at the end
of the study (M12, LOCF) in the PPS was similar to that in the FAS.
Mean percent change (SD) from baseline in (L2–L4) BMD in the
FAS at 6 months in the 2.5 mg once-daily and 75 mg once-monthly
treatment groups was 5.01 (3.62)% and 4.67 (4.16)%, respectively,
and at 12 months it was 5.81 (4.02)% and 6.11 (4.50)%, respectively
(Fig. 2). These data suggest that mean percent change from baseline in
(L2–L4) BMD was increased by similar amounts in the two treatment
groups over the course of this 12-month study.
Biochemical markers of bone metabolism
Mean percent changes from baseline in biochemical markers of the
bone formation marker serum BAP, and the bone resorption markers
serum TRACP-5b, urinary DPD/CRN, urinary NTX/CRN, and urinary
CTX/CRN were generally comparable in the two treatment groups.
Bone resorption markers started to decrease from 1 month after the
ﬁrst treatment of study drug while the bone formation marker startedTable 1
Summary of baseline demographics and characteristics of randomized subjects.
Parameters Risedronate dosage
2.5 mg
once-daily
75 mg
once-monthly
Number of subjects 429 423
Age (years) 68.2 ± 6.85 67.7 ± 6.73
Gender (male/female) 8/421 5/418
BMI (kg/m2) 21.4 ± 2.8 21.9 ± 3.1
Number of years since menopause
(years)
N = 346 N = 353
18.1 ± 7.5 17.4 ± 7.5
Mean lumbar spine BMD (L2–L4 BMD)
measured by DXA
(g/cm2) 0.64 ± 0.06 0.64 ± 0.07
T-score −3.11 ± 0.54 −3.12 ± 0.55
Number of prevalent fractures (Th4-L4), n (%)
0 338 (79.0) 317 (75.1)
1 61 (14.3) 79 (18.7)
2 19 (4.4) 21 (5.0)
3 or more 10 (2.3) 5 (1.2)
Fragility fracture, n (%) Present 121 (28.2) 132 (31.2)
Absent 308 (71.8) 291 (68.8)
History of bisphosphonate administration 36 (8.4%) 33 (7.8%)
Serum 25-OH-D (ng/mL) 21.3 ± 6.9 20.7 ± 6.9
Serum BAP (U/L) 26.1 ± 8.4 26.4 ± 8.9
Serum TRACP-5b (mU/dL) 473 ± 163 457 ± 170
Urinary DPD/CRN (nmol/mmolCRE) 7.65 ± 2.71 7.64 ± 2.65
Urinary NTX/CRN (nmolBCE/mmolCRE) 57.8 ± 22.8 55.6 ± 22.8
Urinary CTX/CRN (μg/mmolCRE) 328 ± 151 307 ± 142
Values are mean ± SD unless speciﬁed otherwise.to decrease from 3 months after the ﬁrst treatment of study drug.
The reductions were maintained to the 12-month time point in both
treatment groups (Fig. 3). The mean percent change from baseline in
urinary NTX/CRN and urinary CTX/CRN levels showed a statistically sig-
niﬁcant decrease in the 2.5 mg once-daily group compared with the
75 mg once-monthly group throughout the treatment period (at 1, 3,
6, 9, 12 months, and at the end of the study [M12, LOCF]).
The results of the subgroup analysis showed that the mean percent
changes from baseline in (L2–L4) BMD at the end of the study (M12,
LOCF) were similar between treatment groups in each subgroup of the
biochemical markers (Table 2). The mean percent changes from base-
line in (L2–L4) BMD at the end of the study (M12, LOCF) were generally
higher in both treatment groups for the subgroup of subjects with
higher baseline values of biochemical markers.
Frequency of vertebral fractures
Thoracic vertebra and lumbar spine X-ray images were taken at base-
line and at the end of the study. The frequency of new vertebral fractures
(including aggravation of prevalent fractures) at the end of the study
(M12, LOCF) was 1.2% (5/410 subjects) in the 2.5 mg once-daily group
and 1.3% (5/393 subjects) in the 75 mg once-monthly group. The differ-
ence between treatment groups was 0.1% (95% CI, −1.48% to 1.59%)
and, thus, the effects of both treatment regimens were similar.
Safety and tolerability
Safety and tolerability were evaluated using the safety analysis
set. The frequency of AEs was similar between the two groups:
82.2% (352/428 subjects) in the 2.5 mg once-daily group and 86.5%
(365/422 subjects) in the 75 mg once-monthly group. In both groups,
the majority of AEs were mild to moderate and the most common
AE was nasopharyngitis (Table 3). The incidence of mild/moderate/
severe AEs was 75.5%/6.3%/0.5% in the 2.5 mg once-daily group and
77.7%/8.1%/0.7% in the 75 mg once-monthly group.
The incidence of AEs counted as non-vertebral fractures was 3.0%
(13/428 subjects) in the 2.5 mg once-daily group and 2.1% (9/422 sub-
jects) in the 75 mg once-monthly group, but these were considered to
be unrelated to the study drug. Furthermore, no cases of AEs associated
with non-traumatic atypical fracture of the subtrochanteric or mid-
shaft of the femur were observed.
The frequency of AEs associatedwith gastrointestinal symptomswas
26.2% (112/428 subjects) in the 2.5 mg once-daily group and 30.8%
(130/422 subjects) in the 75 mg once-monthly group; all of these AEs
were mild to moderate and no severe events were observed. Among
AEs associated with gastrointestinal symptoms, diarrhea was remark-
able as its frequency was higher in the 75 mg once-monthly group
Fig. 3.Mean percent change from baseline in biochemicalmarkers of bonemetabolism (FAS) (BAP = bone alkaline phosphatase; DPD, deoxypyridinoline; CRN, creatinine; NTX, collagen
type 1 cross-linked N-telopeptide; CTX, collagen type 1 cross-linked C-telopeptide; TRACP-5b, tartrate-resistant acid phosphatase 5b). End of study refers to the value calculation using the
last observation carried forward at Month 12. *Statistically signiﬁcant difference between treatment groups (unadjusted for multiple comparisons). **Number of subjects for serum BAP
and TRACP-5b; corresponding number of subjects for urinary DPD/CRN, NTX/CRN and CTX/CRN = 404.
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18/428 subjects). AEs potentially associated with APR only occurred in
the 75 mg once-monthly group (2.1%, 9/422 subjects; inﬂuenza-like
symptoms in 1 subject and pyrexia in 8 subjects). The incidence was
low, 8 events were mild and 1 event was moderate (pyrexia).
The frequency of serious AEs (including death) was 4.4% (19/428
subjects) in the 2.5 mg once-daily group and 5.7% (24/422 subjects) in
the 75 mg once-monthly group. Serious AEs that were “related” to the
study drug occurred in one subject in each group: adjustment disorderin one subject (2.5 mg once-daily group) and cerebrovascular disorder
in the other subject (75 mg once-monthly group). One subject (75 mg
once-monthly group) died during the study (due to drowning), but it
was considered to be unrelated to the study drug. Treatment was
discontinued due to AEs in 7.2% of subjects (31/428 subjects) in the
2.5 mg once-daily group and 9.7% of subjects (41/422 subjects) in the
75 mg once-monthly group.
Therewere no clinically signiﬁcant changes in themean values of vital
signs and laboratory tests, compared with baseline, in the two groups.
Table 2
Subgroup analysis stratiﬁed on mean percent change from baseline in lumbar spine (L2–L4) BMD at the end of treatment period as measured by DXA (FAS).
Stratiﬁcation factors Treatment groups Percent change (%)
N Mean SD
Serum BAP (U/L) Min≤–≤21.1 2.5 mg once-daily 115 4.687 3.8147
75 mg once-monthly 107 3.934 4.1973
21.2≤–≤29.0 2.5 mg once-daily 171 5.515 3.7700
75 mg once-monthly 151 6.290 4.2701
29.1≤–≤Max 2.5 mg once-daily 122 6.893 4.2048
75 mg once-monthly 134 7.256 4.5687
Serum TRACP-5b (mU/dL) Min≤–≤119 2.5 mg once-daily 1 1.760
75 mg once-monthly 1 5.260
120≤–≤420 2.5 mg once-daily 177 4.984 3.6938
75 mg once-monthly 174 5.206 4.3975
421≤−≤Max 2.5 mg once-daily 230 6.257 4.1442
75 mg once-monthly 217 6.599 4.5774
Urinary DPD/CRN (nmol/mmolCRE) Min≤–≤5.9 2.5 mg once-daily 106 5.055 3.7247
75 mg once-monthly 111 4.827 3.9250
6.0≤–≤7.6 2.5 mg once-daily 142 5.742 4.1414
75 mg once-monthly 119 6.802 4.7337
7.7≤–≤Max 2.5 mg once-daily 160 6.074 4.0205
75 mg once-monthly 162 6.160 4.6541
Urinary NTX/CRN (nmolBCE/mmolCRE) Min≤–≤35.3 2.5 mg once-daily 56 3.934 3.4550
75 mg once-monthly 71 4.429 4.1685
35.4≤–≤54.3 2.5 mg once-daily 149 5.325 4.1529
75 mg once-monthly 133 5.467 4.7575
54.4 ≤–≤ Max 2.5 mg once-daily 203 6.450 3.8492
75 mg once-monthly 188 6.923 4.3151
Urinary CTX/CRN (μg/mmolCRE) Min≤–≤184.1 2.5 mg once-daily 62 4.328 3.8913
75 mg once-monthly 68 4.190 4.0522
184.2≤–≤301.4 2.5 mg once-daily 140 5.358 4.0775
75 mg once-monthly 145 5.771 4.3580
301.5≤–≤Max 2.5 mg once-daily 206 6.333 3.8646
75 mg once-monthly 179 6.823 4.6643
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The primary endpoint in this Japanese phase III study (mean percent
change in lumbar spine (L2–L4) BMD frombaseline to the endof the study
[M12, LOCF]) demonstrated that risedronate 75 mg once-monthly, a 30
times higher dosage compared to risedronate 2.5 mg once-daily, hadTable 3
Summary of adverse events (AEs).
Parameters 2.5 mg once-daily 75 mg once-monthly
Number of subjects 428 422
Total number of subjects with AE 352 (82.2%) 365 (86.5%)
Serious AEs 19 (4.4%) 24 (5.7%)
Number of subjects in whom treatment
was discontinued due to AE
31 (7.2%) 41 (9.7%)
AEs occurring in ≥5% of subjects
Nasopharyngitis 108 (25.2%) 119 (28.2%)
Upper respiratory tract inﬂammation 14 (3.3%) 21 (5.0%)
Abdominal discomfort 27 (6.3%) 28 (6.6%)
Diarrhea 18 (4.2%) 35 (8.3%)
Constipation 28 (6.5%) 19 (4.5%)
Eczema 20 (4.7%) 24 (5.7%)
Back pain 26 (6.1%) 35 (8.3%)
Osteoarthritis 23 (5.4%) 24 (5.7%)
Fall 27 (6.3%) 39 (9.2%)
Contusion 26 (6.1%) 32 (7.6%)
Adverse events of special interest
Non-vertebral fracturea 13 (3.0%) 9 (2.1%)
Adverse events associated with
gastrointestinal symptomsb
112 (26.2%) 130 (30.8%)
Adverse events potentially associated
with acute phase reactionc
0 9 (2.1%)
a Includes all fractures except those occurring in vertebra.
b Includes events that are classiﬁed in accordance with the MedDRA SOC as “Gastroin-
testinal disorders”, excluding the preferred terms referring to oral and anal conditions
and including the preferred terms “Gastroenteritis” (SOC “Infections and infestations”).
c Includes symptoms of inﬂuenza-like illness or pyrexia with a starting date within the
ﬁrst 3 days after the ﬁrst dose of study drug and a duration of 7 days or less.non-inferior efﬁcacy to the once-daily regimen in Japanese patients
with involutional osteoporosis. In the multinational phase III study,
excluding Japan (ex-Japan), the efﬁcacy of risedronate 150 mg once-
monthly, which is twice the dose used in this Japanese phase III study,
was non-inferior to risedronate 5 mg once-daily in patients with involu-
tional osteoporosis [7,23].
Doses of risedronate administered daily, weekly, and monthly in
Japan are different from those used outside Japan. It has been reported
that the result of the Japanese risedronate once-daily phase I study
suggested differences in risedronate bioavailability between Japanese
and non-Japanese subjects, although the reasons for this difference
remain unknown [8].
With regard to biochemical markers of bone metabolism, the
bone resorption markers (serum TRACP-5b, urinary DPD/CRN, urinary
NTX/CRN and urinary CTX/CRN) started to decrease from 1 month
after the ﬁrst dose of the study drug and the bone formation marker
(serum BAP) started to decline from 3 months after the ﬁrst dose
of the study drug. In both groups, the low levels achieved for these
markers were maintained for the 12-month duration of the study,
with only small ﬂuctuations.
Both treatment groups showed clinically signiﬁcant decreases in
urinary NTX/CRN and CTX/CRN levels from baseline to the end of the
study (M12, LOCF), but the reduction was statistically larger in the
2.5 mg once-daily group compared with the 75 mg once-monthly
group throughout the treatment period. However, the between-group
differences for these markers do not appear to be clinically signiﬁcant,
because the mean percent change in lumbar spine (L2–L4) BMD was
similar in both groups from baseline to the end of the study (M12,
LOCF). With regard to the between-group differences in NTX/CRN and
CTX/CRN, a possible reason may be that the measurement time points
were different in both treatment groups. For the 2.5 mg once-daily
group, the sample for biochemical markers of bone metabolism was
taken after administration of risedronate on the morning of the visit.
However, for the 75 mg once-monthly group, the sample was taken
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in the morning on at least a day after the visit). In a multinational
phase II study (ex-Japan), the reduction in serum CTX levels was larger
in the 5 mgonce-daily group comparedwith the 150 mg once-monthly
group on Day 30 of Month 5 but the reduction was larger in the 150 mg
once-monthly group compared with the 5 mg once-daily group on Day
4 and 14 of Month 6 after administration of Month 6. Following a grad-
ual recovery of the serum CTX levels in the 150 mg once-monthly
group, CTX levels in the 5 mg once-daily group were larger than those
in the 150 mg once-monthly group on Day 30 of Month 6. The pattern
of change in urinary NTX levels was similar to that in serum CTX levels
[24]. In a phase I study in Japan (not published), after single administra-
tion of risedronate 75 mg, both urinary NTX/CRN and CTX/CRN de-
creased markedly, reaching the maximum decrease after 48 h (−63%
and −76%, respectively) and, then, gradually recovering (−8% and
−29% after 720 h, respectively). In our study, we believe that the
marked short-term (within a short period of time after each administra-
tion) reduction in urinary CTX/CRN and NTX/CRN levels in the once-
monthly group (75 mg) concurs with the reductions observed in the
multinational phase II study (ex-Japan) and the phase I study in Japan.
Therefore, it is thought that the effects of risedronate once-monthly
(75 mg) and once-daily (2.5 mg) on these bone resorption markers are
similar when comparing the area under the effect–time curve for urinary
CTX/CRN and urinary NTX/CRN. Furthermore, in amultinational phase III
(ex-Japan) study of risedronate at Month 12 (2-year randomized,
double-blind, multicenter study comparing once-monthly risedronate
150 mg with a 5 mg once-daily regimen) [7], a similar pattern to that
observed in the current phase III study in Japan was reported, such that
the reduction in urinary NTX/CRN and serum CTX levels from baseline
to the end of the study was slightly larger in the once-daily compared
with the once-monthly group.
In the current study, the percent changes in other biochemical
markers (serum TRACP-5b, urinary DPD/CRN, serum BAP) were similar
in the two treatment groups. Among the biochemical markers, serum
TRACP-5b is a marker that has become available recently. The result of
the subgroup analysis for serum TRACP-5b was in line with the results
of other biochemical markers, showing higher mean percent changes
from baseline in (L2–L4) BMD at the end of the study (M12, LOCF) in
the subgroup of subjects with higher baseline values. Additionally, all
biochemical markers showed a clinically signiﬁcant change from base-
line at the end of the study (M12, LOCF), including the percent change
for serum TRACP-5b of approximately−40%, where 12.4% is the mini-
mum signiﬁcant change previously reported for serum TRACP-5b [25].
In order to further explore the relationship between BMD and the bio-
chemical markers, Spearman correlation coefﬁcients were calculated.
The correlation coefﬁcients between the primary endpoint and the
percent change at the end of the study (M12, LOCF) for the biochemical
markers, serum BAP, urinary DPD/CRN, urinary NTX/CRN, urinary
CTX/CRN, and serum TRACP-5b, were −0.378, −0.196, −0.341,
−0.248, and −0.378, respectively. Serum TRACP-5b had a correla-
tion coefﬁcient similar to that of other biochemical markers, demon-
strating it to be as useful a marker as the other biochemical markers
in monitoring risedronate treatment.
The frequency of new vertebral fractures (including aggravation of
prevalent vertebral fractures) at the end of the study (M12, LOCF) was
shown to be similar in the two treatment groups. The incidence of non-
vertebral fractures was numerically smaller in the 75 mg once-monthly
group than in the 2.5 mg once-daily group [2.1% (9/422) vs. 3.0%
(13/428), respectively]. The vertebral antifracture efﬁcacy of once-
daily regimens has been veriﬁed in clinical trials. The clinical literature
advocates BMD as a surrogate marker for vertebral antifracture efﬁcacy
[26]. In the current study, 75 mg once-monthly was non-inferior
to 2.5 mg once-daily in mean percent change from baseline in BMD,
suggesting that once-monthly risedronate could be expected to possess
antifracture efﬁcacy similar to that observed with the once-daily
regimen.Similar to other bisphosphonates, risedronate is absorbed rapidly
into bone tissue after administration but it is not readily degraded
in vivo, resulting in an extremely long half-life in bone. Intermittent ad-
ministration of risedronate is considered to have the same effect as daily
administration where appropriate dose and dosing intervals have been
established. In the current study, subjects in the 75 mg once-monthly
group received a larger amount of drug per administration than did
those in the 2.5 mg once-daily group, which results in the same total
dose in amonth. Stepensky and colleagues reported that lower amounts
of alendronate were found in the bone of thyroidparathyroidectomy
(TPTX) rats 1 day after the administration of alendronate as a 2-week
continuous input from a subcutaneously implanted osmotic pump as
compared with intermittent bolus administration of the same dose in
total [27]. Therefore, it was considered that the amount of accumulation
of bisphosphonate within bone after each single intermittent dose
was more than that obtained with continuous administration. It was
considerable that the amount of risedronate accumulation is higher in
the 75 mg once-monthly group than in the 2.5 mg once-daily group
after each single 75 mg once-monthly group treatment. Therefore,
each administration of risedronate 75 mg once-monthly, which has a
larger accumulation in bone, is possibly associated with more
diffusion in bone than 2.5 mg once-daily administration. Therefore, it
may be possible that this difference of distribution in bone between
daily and monthly risedronate administration causes the difference
in the prevention of bone fracture, but further research is required to
obtain more data.
With regard to safety, the frequency of overall AEs, gastrointestinal
AEs (which are typical AEs during bisphosphonate therapy), serious
AEs, and the number of subjects for whom treatment was discontinued
due to AEs, were comparable in the two treatment groups.
The frequency of AEs associated with gastrointestinal symptoms was
similar between treatment groups. There was no notable difference in
baseline demographics, complications, andmedical history between sub-
jects who had developed AEs associated with gastrointestinal symptoms
and those who had not. AEs associated with gastrointestinal symptoms
developedmost frequently during the period from the initial administra-
tion to Day 30; the frequency of new onset of gastrointestinal symptoms
tended to decrease thereafter in each of the treatment groups (data not
presented). One of the AEs, diarrhea, was remarkable as its frequency
was higher in the 75 mg once-monthly group than in the 2.5 mg once-
daily group. However, the number of subjects who discontinued due to
diarrhea did not differ signiﬁcantly between the two treatment groups
(4 and 5 subjects in the 2.5 mg once-daily and 75 mg once-monthly
groups, respectively) and its severity was mild or moderate.
Inﬂuenza-like illness associated with both IV and oral bisphos-
phonates is transitory and self-limiting and usually does not recur
after subsequent drug administration. This inﬂuenza-like illness is re-
ferred to as APR [28]. In the current study, AEs potentially associated
with APRs only occurred in the 75 mg once-monthly group; the inci-
dence was low, severity was mild or moderate, and these events
were not considered to be clinically important. In the multinational
(ex-Japan) phase III study, AEs potentially associated with APRs
occurred at a similarly low rate as in our study; 1.4% (9/650) of subjects
treated with risedronate 150 mg once-monthly and 0.2% (1/642) of
subjects treatedwith 5 mg once-daily [7]. It is considered that the treat-
ment of APRswith analgesics such as paracetamol is generally sufﬁcient
to manage them [29]. Overall, with regard to safety, risedronate 75 mg
once-monthlywas similarlywell tolerated comparedwith 2.5 mgonce-
daily in Japanese patients with involutional osteoporosis.
A potential limitation of the current study, in terms of generalizabil-
ity of results, relates to the fact that there were only 5 male participants
in the 75 mg once-monthly group. Consequently, we need to accumu-
late clinical experience in males with osteoporosis through post-
marketing surveillance, etc., to fully assess the efﬁcacy and tolerability
of monthly risedronate in this population. It is also important to note
that the current study is of primary interest to the Japanese population;
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multinational (ex-Japan) phase III study in, for example, the study envi-
ronment and study design, the results of the multinational (ex-Japan)
phase III study [7] are mentioned here brieﬂy, for reference. The mean
percent change in lumbar spine (L1–L4) BMD (primary endpoint) at 12 -
months (LOCF)was 3.4% (95% CI, 3.03% to 3.82%) in the 5 mg once-daily
group and 3.5% (95% CI, 3.15% to 3.93%) in the 150 mg once-monthly
group. The once-monthly regimen was determined to be non-inferior
to the daily regimen with respect to changes in lumbar spine BMD by
analysis using an ANOVA model with treatment and pooled centers as
ﬁxed effects. Mean lumbar spine (L1–L4) BMD T-score (SD) at baseline
was −3.18 (0.56) in the 5 mg once-daily group and −3.21 (0.57) in
the 150 mg once-monthly. With regard to safety, the overall frequency
of AEs was 78.5% (504/642) in the 5 mg once-daily group and 79.2%
(515/650) in the 150 mg once-monthly group at 12 months [7].
Risedronate 150 mg once-monthly has been approved in the US since
April 2008.
In conclusion, in Japanese patients with involutional osteoporosis,
once-monthly risedronate 75 mg, which is 30 times the dose of once-
daily risedronate, was shown to be non-inferior in efﬁcacy to risedronate
2.5 mg once-daily. With regard to safety, risedronate 75 mg once-
monthly was similarly well tolerated compared with 2.5 mg once-daily.
Clinical beneﬁt with once-monthly risedronate 75 mg in Japanese pa-
tientswas achieved using half the dose (150 mg) administered in studies
conducted outside Japan. This is consistent with the daily and weekly
doses (2.5 mg and 17.5 mg, respectively) used in Japan being half the
daily and weekly doses (5 mg and 35 mg, respectively) used outsideStudy site
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Appendix A
Other members of the current studyJapan. Monthly risedronate offers patients with osteoporosis a new dos-
age option which may improve convenience, as well as improving treat-
ment adherence, for those who are having difﬁculty complying with the
daily and weekly regimens.
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